FMFrancesco Marrafino

Francesco Marrafino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Marrafino has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Theoretical investigation of hydroxylated analogues of valinomycin as potassium transporter

    by Lucia Sessa, Simona Concilio, Francesco Marrafino, Arkadeep Sarkar, Rosita Diana, Stefano Piotto


  • Open Access

    GUIDE: A GUI for automated quantum chemistry calculations

    by Arkadeep Sarkar, Lucia Sessa, Francesco Marrafino, Stefano Piotto

    The accuracy of quantum mechanics (QM) simulations depends heavily on the quality of initial input files. Despite the popularity of QM simulation packages, achieving precise results still heavily relies on the user's proficiency in preparing the QM simulation systems. In this work, we present an easy‐to‐use tool called GUIDE, a YASARA plugin to assist researchers in quantum chemistry workflow automation using ORCA and MOPAC simulation packages. GUIDE lets users compute complex QM calculation workflows via an automated graphical window system. It allows for a more integrated and streamlined research process, as researchers can easily access all the necessary tools within one software without switching between multiple programs. This tool can save time and increase efficiency in computational chemistry methods. GUIDE is written in Python and is freely available for download at https://github.com/YAMACS-SML/GUIDE. The plugin is released under a GPL‐3.0 license and is supported on Windows and Linux.


  • YAMACS: a graphical interface for GROMACS

    by Arkadeep Sarkar, Jacopo Santoro, Luigi Di Biasi, Francesco Marrafino, Stefano Piotto

    A graphical user interface for the GROMACS program has been developed as plugins for YASARA molecular graphics suite. The most significant GROMACS methods can be run entirely via a windowed menu system, and the results are shown on screen in real time. YAMACS is written in Python and is freely available for download at https://github.com/YAMACS-SML/YAMACS and is supported on Linux. It has been released under GPL-3.0 license. Supplementary data are available at Bioinformatics online.


  • Open Access

    Evaluating Epidemiological Risk by Using Open Contact Tracing Data: Correlational Study

    by Stefano Piotto, Luigi Di Biasi, Francesco Marrafino, Simona Concilio

    Background: During the 2020s, there has been extensive debate about the possibility of using contact tracing (CT) to contain the SARS-CoV-2 pandemic, and concerns have been raised about data security and privacy. Little has been said about the effectiveness of CT. In this paper, we present a real data analysis of a CT experiment that was conducted in Italy for 8 months and involved more than 100,000 CT app users. Objective: We aimed to discuss the technical and health aspects of using a centralized approach. We also aimed to show the correlation between the acquired contact data and the number of SARS-CoV-2–positive cases. Finally, we aimed to analyze CT data to define population behaviors and show the potential applications of real CT data. Methods: We collected, analyzed, and evaluated CT data on the duration, persistence, and frequency of contacts over several months of observation. A statistical test was conducted to determine whether there was a correlation between indices of behavior that were calculated from the data and the number of new SARS-CoV-2 infections in the population (new SARS-CoV-2–positive cases). Results: We found evidence of a correlation between a weighted measure of contacts and the number of new SARS-CoV-2–positive cases (Pearson coefficient=0.86), thereby paving the road to better and more accurate data analyses and spread predictions. Conclusions: Our data have been used to determine the most relevant epidemiological parameters and can be used to develop an agent-based system for simulating the effects of restrictions and vaccinations. Further, we demonstrated our system's ability to identify the physical locations where the probability of infection is the highest. All the data we collected are available to the scientific community for further analysis.


  • Open Access

    Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir

    by Marie O. Pohl, Idoia Busnadiego, Francesco Marrafino, Lars Wiedmer, Annika Hunziker, Sonja Fernbach, Irina Glas, Elena V. Moroz-Omori, Benjamin G. Hale, Amedeo Caflisch, et al.

    Rapid repurposing of existing drugs as new therapeutics for COVID-19 has been an important strategy in the management of disease severity during the ongoing SARS-CoV-2 pandemic. Here, we used high-throughput docking to screen 6000 compounds within the DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3 CL main protease, a chymotrypsin-like enzyme that is essential for viral replication. For 19 candidate hits, parallel in vitro fluorescence-based protease-inhibition assays and Vero-CCL81 cell-based SARS-CoV-2 replication-inhibition assays were performed. One hit, diclazuril (an investigational anti-protozoal compound), was validated as a SARS-CoV-2 3 CL main protease inhibitor in vitro (IC50 value of 29 µM) and modestly inhibited SARS-CoV-2 replication in Vero-CCL81 cells. Another hit, lenvatinib (approved for use in humans as an anti-cancer treatment), could not be validated as a SARS-CoV-2 3 CL main protease inhibitor in vitro, but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit SARS-CoV-2 replication, albeit this was specific to Vero-CCL81 cells. Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, but the synergistic effect with remdesivir was not observed with other approved RTK inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is independent of host RTKs. Furthermore, time-of-addition studies revealed that lenvatinib/remdesivir synergy probably targets SARS-CoV-2 replication subsequent to host-cell entry. Our work shows that combining computational and cellular screening is a means to identify existing drugs with repurposing potential as antiviral compounds. Future studies could be aimed at understanding and optimizing the lenvatinib/remdesivir synergistic mechanism as a therapeutic option.


  • Open Access

    Evaluating Epidemiological Risk by Using Open Contact Tracing Data: Correlational Study (Preprint)

    by Stefano Piotto, Luigi Di Biasi, Francesco Marrafino, Simona Concilio

    BACKGROUND During the 2020s, there has been extensive debate about the possibility of using contact tracing (CT) to contain the SARS-CoV-2 pandemic, and concerns have been raised about data security and privacy. Little has been said about the effectiveness of CT. In this paper, we present a real data analysis of a CT experiment that was conducted in Italy for 8 months and involved more than 100,000 CT app users. OBJECTIVE We aimed to discuss the technical and health aspects of using a centralized approach. We also aimed to show the correlation between the acquired contact data and the number of SARS-CoV-2–positive cases. Finally, we aimed to analyze CT data to define population behaviors and show the potential applications of real CT data. METHODS We collected, analyzed, and evaluated CT data on the duration, persistence, and frequency of contacts over several months of observation. A statistical test was conducted to determine whether there was a correlation between indices of behavior that were calculated from the data and the number of new SARS-CoV-2 infections in the population (new SARS-CoV-2–positive cases). RESULTS We found evidence of a correlation between a weighted measure of contacts and the number of new SARS-CoV-2–positive cases (Pearson coefficient=0.86), thereby paving the road to better and more accurate data analyses and spread predictions. CONCLUSIONS Our data have been used to determine the most relevant epidemiological parameters and can be used to develop an agent-based system for simulating the effects of restrictions and vaccinations. Further, we demonstrated our system's ability to identify the physical locations where the probability of infection is the highest. All the data we collected are available to the scientific community for further analysis.


  • Fluorescent Probes for Applications in Bioimaging

    by Miriam Di Martino, Francesco Marrafino, Rosita Diana, Pio Iannelli, Simona Concilio


  • Molecular Dynamics Simulation of Antimicrobial Permeable PVC-Based Films

    by Lucia Sessa, Anna Maria Nardiello, Miriam Di Martino, Francesco Marrafino, Pio Iannelli

  • Superhydrophobic Coatings and Artificial Neural Networks: Design, Development and Optimization

    by Francesco Marrafino, Pio Iannelli, Miriam Di Martino, Simona Concilio, Stefano Piotto


  • Open Access

    Novel Dicyano-Phenylenevinylene Fluorophores for Low-Doped Layers: A Highly Emissive Material for Red OLEDs

    by Rosita Diana, Barbara Panunzi, Francesco Marrafino, Stefano Piotto, Ugo Caruso

    Two efficient deep red (DR)-emitting organic dicyano-phenylenevinylene derivatives with terminal withdrawing or donor groups were synthesized. The spectroscopic properties of the neat solids and the low-doped layers in polystyrene or polyvinylcarbazole host matrixes were analyzed, and the luminescence performance was explained using density functional theory (DFT) analysis. A noteworthy 89% fluorescence quantum yield was observed for the brightest red-emissive polyvinylcarbazole (PVK) blend. This result pushed us to successfully produce an emissive red organic light-emitting device (OLED) as a preliminary feasibility test.